Wang X, Xu Y, Norman G, et al. CGM Use in People with Type 2 Diabetes Initiating GLP-1 or GIP/GLP-1RA Therapy—Real-World Data. Diabetes. June 14, 2024.

Recently, researchers published new insights in Diabetes exploring the use of continuous glucose monitoring (CGM) in patients with type 2 diabetes (T2D) prior to and after initiating GLP-1 medications.

Using Truveta Data, researchers analyzed patients diagnosed with T2D aged 30 and older from 2018 to 2022. They explored three different cohorts: intensive-insulin treated, basal-insulin treated, and non-insulin treated, then evaluated their use of CGM both before and after initiating GLP-1 medications.

The analysis of 299,157 patients found that the use of CGM in people with T2D has increased significantly over the study period, with greater use following the initiation of GLP-1 medications, independent of insulin use.